Grant: Operating Grant: Industry-partnered Collaborative Research
McMaster University
$295,386.00
Development of peptide immunotherapy for Rheumatoid Arthritis: Identification and validation of T cell epitopes from citrullinated auto-antigens.
EF 2014-15
Résumé
Rheumatoid arthritis (RA) is a chronic disease affecting approximately 1% of the Canadian population. It primarily causes pain, swelling and motion limitations in joints, but it can also develop in other organs as well. Unfortunately, the current treatments are non-specific, expensive and they are associated with serious side effects.
RA is an autoimmune disorder, as the immune system mistakenly attacks its own body's tissues. It is not clear how the disease starts. Existing research suggests that, on top of genetic factors, one of the triggers for RA may be a change in one amino acid called arginine. An enzyme in the body called PAD can change arginine amino acids into an unnatural amino acid called citrulline. As a consequence, natural proteins in the body that contain the amino acid arginine are changed into proteins with citrulline in them. Because the immune system has never seen these new proteins before, it attacks them, causing inflammation, especially in the joints. A type of white blood cell called "CD4+ T cells" can detect the changed amino acids in small fragments of the new proteins. The fragments are called "peptides" or "epitopes". These peptides trigger the T cells to make and release signals (called "cytokines") that drive inflammation in the joints. Our proposed study aims to identify the citrullinated peptides/epitopes responsible for driving RA. We have previously used similar peptides to treat people with allergic diseases and reduce their symptoms. We are confident that we can do the same thing in RA, as long as we can identify the right peptides to use. That is the purpose of this grant.
Programme
Operating Grant: Industry-partnered Collaborative Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
324765
Name
Larche Mark
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Adiga Life Sciences Inc. (Hamilton, Ontario)
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Development of peptide immunotherapy for Rheumatoid Arthritis: Identification and validation of T cell epitopes from citrullinated auto-antigens.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$295,386
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research
Keyworddelim
Epitope Discovery; Immunotherapy; Rheumatoid Arthritis; Rheumatoid Arthritis Treatment; T Cell; Therapeutic Tolerance
Abstract
Rheumatoid arthritis (RA) is a chronic disease affecting approximately 1% of the Canadian population. It primarily causes pain, swelling and motion limitations in joints, but it can also develop in other organs as well. Unfortunately, the current treatments are non-specific, expensive and they are associated with serious side effects.
RA is an autoimmune disorder, as the immune system mistakenly attacks its own body's tissues. It is not clear how the disease starts. Existing research suggests that, on top of genetic factors, one of the triggers for RA may be a change in one amino acid called arginine. An enzyme in the body called PAD can change arginine amino acids into an unnatural amino acid called citrulline. As a consequence, natural proteins in the body that contain the amino acid arginine are changed into proteins with citrulline in them. Because the immune system has never seen these new proteins before, it attacks them, causing inflammation, especially in the joints. A type of white blood cell called "CD4+ T cells" can detect the changed amino acids in small fragments of the new proteins. The fragments are called "peptides" or "epitopes". These peptides trigger the T cells to make and release signals (called "cytokines") that drive inflammation in the joints. Our proposed study aims to identify the citrullinated peptides/epitopes responsible for driving RA. We have previously used similar peptides to treat people with allergic diseases and reduce their symptoms. We are confident that we can do the same thing in RA, as long as we can identify the right peptides to use. That is the purpose of this grant.
Competitiondate
201503
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Larche, Mark; Tonti, Elena
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $295,386~ $0~